Badger Meter (BMI) Q1 2026 Earnings Transcript

Badger Meter reported Q1 sales of $202 million, down 9% year over year, with diluted EPS of $0.93 versus $1.30 last year as weaker short-cycle orders and AMI project timing pressured results. Gross margin held relatively firm at 41.7% and free cash flow was about $30 million, but SEA expenses rose $3.1 million and operating margin fell to 17.4% from 22.2%. Management reaffirmed a 39%-42% gross margin target, said full-year 2026 organic revenue should be roughly in line with 2025, and announced a $100 million UDLive acquisition plus continued share repurchases.

Analysis

The market is likely underestimating how much of the quarter’s weakness is self-correcting operating noise versus a real demand break. The key second-order effect is that BMI’s project funnel has become more visible precisely because the backlog cushion is gone; that creates ugly near-term comps but also sets up a cleaner 2027 earnings bridge if deployments simply execute on schedule. In other words, the “miss” is compressing valuation on a mechanically lumpy business just as the next multi-year cohort is larger than the prior one.

The more interesting change is mix, not demand. BMI is shifting toward software, monitoring, and competitively won AMI conversions, which should carry higher lifetime value than the quarter’s headline gross margin suggests, even if near-term project margins are uneven. The acquisition of UDLive is strategically small but important: it expands the installed base thesis into a geographically adjacent regulated market, and management is effectively signaling that the addressable sewer-monitoring market is still in the early adoption phase, so growth can compound for years with limited penetration risk.

What the consensus may miss is that the current margin pressure is probably the best setup for capital deployment in 12 months, not the worst. If revenue normalizes into the back half while SEA stays disciplined, operating leverage can re-accelerate sharply because the company is already preserving price and cash flow. The main downside is schedule slippage on late-start projects into 2027, which would extend the air pocket and keep the stock de-rated, but that looks like a timing risk rather than a structural one unless short-cycle weakness broadens into distributor inventory destocking or municipal capex compression.

Key Decisions for Investors

• Buy BMI on weakness over the next 1-2 sessions as a 6-12 month re-rating trade; target a rebound into Investor Day and Q2 prints if project starts and short-cycle orders improve sequentially. Risk/reward favors entry because current pressure is mostly timing-driven while 2027 visibility is improving.
• Use a call spread in BMI (3-6 month tenor) to express back-half recovery with defined risk; the setup is for upside if Q2 is merely a trough and Q3/Q4 show sequential revenue improvement. Prefer spreads over outright shares because near-term volatility remains high.
• Pair long BMI vs short a lower-quality water/industrial equipment name with weaker software mix and less project visibility; BMI has better mix migration and capital return support, while the short leg should be more exposed to pure volume deleverage.
• If BMI rallies hard into Investor Day, trim 25-30% and keep a core position for 2027 execution; the stock can re-rate on visibility, but the first move likely over-discounts a clean recovery path that still has execution risk.
• Avoid chasing after one strong quarter-end print; the cleaner entry is on any evidence that late-start project timing slips again, because that would likely be a temporary drawdown rather than a thesis break.